The purpose of this study is to determine if buccal administration of a concentrated formulation of long-chain polyunsaturated fatty acids (LCPUFA) can help to maintain docosahexaenoic acid (DHA) levels in extremely low birth weight (ELBW) infants.
This will be a multi-center, randomized, placebo controlled, double blind trial. Two doses of PUFA will be compared to placebo- a "high" dose and a "low" dose. ELBW infants will be enrolled into this study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
30
Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Prentice Women's Hospital
Chicago, Illinois, United States
NorthShore University HealthSystem
Evanston, Illinois, United States
Long-chain Polyunsaturated Fatty Acid (LCPUFA) Levels
LCPUFA levels will be measured at 2 weeks of life in extremely low birth weight (ELBW) infants
Time frame: 2 weeks of life
LCPUFA Levels
LCPUFA levels will be measured at 8 weeks of life.
Time frame: 8 weeks of life
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.